Unlock instant, AI-driven research and patent intelligence for your innovation.

Epitope polypeptide of dengue virus type 2 NS3 protein and application thereof

A technology of epitope polypeptide, dengue virus, applied in the field of medicine

Inactive Publication Date: 2013-02-20
ARMY MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, both Escherichia coli and eukaryotic yeast, baculovirus, and mammalian cells have insufficient expression methods, and the purification of recombinant proteins is complicated, making it difficult to avoid changes in protein structure and function
To date, there is still no vaccine that is both safe and effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Epitope polypeptide of dengue virus type 2 NS3 protein and application thereof
  • Epitope polypeptide of dengue virus type 2 NS3 protein and application thereof
  • Epitope polypeptide of dengue virus type 2 NS3 protein and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1, the preparation of material

[0026] Dengue virus type 2 (DV2, Tr1751 strain): preserved by our laboratory.

[0027] Experimental animals: BALB / c mice, 6-8 weeks old, SPF grade, female, weighing 18-22 g, purchased from the Experimental Animal Center of Third Military Medical University.

[0028] Synthetic peptide: synthesized by Shanghai Sangon Bioengineering Co., Ltd., dissolved in dimethyl sulfoxide (DMSO) to a concentration of 5 mg / mL, stored at -70°C, and diluted to 1 mg / mL with phosphate buffered saline (PBS) before use.

[0029] Freund's adjuvant and Freund's incomplete adjuvant were purchased from Sigma, USA; phage peptide library display kit (Ph.D.-7 TM Phage Display Peptide Library Kit), purchased from NEB, USA.

[0030] LB liquid medium: tryptone 10g, yeast extract 5g, NaCl 10g, add distilled water to 1000mL, adjust pH to 7.4, and autoclave sterilization.

[0031] LB solid medium: add 1.5g agar powder to 100mL LB culture medium, and pour th...

Embodiment 2

[0053] Embodiment 2, antibody purification

[0054] (1) Preparation of buffer:

[0055] Equilibrium buffer: 50mM Tris-Cl, 3M NaCl, pH7.8-8.5;

[0056] Elution buffer: 0.1M sodium citrate buffer, pH4.0;

[0057] Regeneration buffer: 0.1M sodium citrate buffer, pH3.0;

[0058] Neutralization buffer: 1M Tris-Cl, pH9.0;

[0059] The above buffers need to be filtered with a 0.45 μm filter membrane before use.

[0060] (2) Sample preparation

[0061] Splenocytes from BALB / c mice immunized with dengue virus type 2 (Tr1751 strain) were fused with myeloma cell SP20, and the positive hybridoma cells prepared were injected into the peritoneal cavity of BALB / c mice to obtain ascites (see Zongtao Chen et al. al. Production of a Monoclonal Antibody Against Non-Structural Protein 3 of Dengue-2 Virus by Intrasplenic Injection). The obtained ascitic fluid was diluted 10 times with the equilibrium buffer to ensure that the composition and pH of the sample liquid were close to the equil...

Embodiment 3

[0069] Example 3. Using phage peptide library to screen antigen epitopes

[0070] 1. Phage screening

[0071] Day 1: Purified 4F5 antibody coated 96-well microplate

[0072] 1. Dissolve the 4F5 antibody prepared in Example 2 in 0.1M NaHCO of pH8.6 3 , prepare a 4F5 antibody solution with a concentration of 100 μg / mL.

[0073] 2. Add 150 μL of the 4F5 antibody solution prepared in step 1 to each well of the 96-well microplate, and rotate repeatedly until the surface is completely wet (be careful not to splash the solution).

[0074] 3. Then put the 96-well microplate into a humidified container (such as a sealable plastic box lined with wet paper towels), and incubate overnight at 4°C with slight shaking.

[0075] the next day

[0076] 4. Pick the single clone of host bacterium ER2738 (the plate that was spread during the phage titer determination) in 20mL LB liquid medium, and culture it with vigorous shaking at 37°C.

[0077] 5. Pour off the coating solution in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses epitope polypeptide of dengue virus type 2 NS3 protein. The amino acid sequence of the epitope polypeptide is shown by SEQ ID No.1, and the specificity and immunogenicity are high; the epitope polypeptide can be directly coupled with the carrier protein to form a crosslinking body to be prepared into a derivative of the epitope polypeptide; and the prepared derivative can be used for preparing a vaccine for preventing the infection of dengue virus type 2, thereby being safe and reliable without toxic side effect and laying foundation for preventing and treating the infection of the dengue virus type 2.

Description

technical field [0001] The invention relates to the field of medicine, in particular to an epitope polypeptide of dengue virus type 2 NS3 protein, and also to derivatives and applications of the epitope polypeptide. Background technique [0002] Dengue virus (DV) is the pathogen that causes human dengue fever (classical dengue fever, DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). In recent years, with the increase of population mobility and global warming, about 100 million people in tropical and subtropical regions are infected by the virus every year, of which about 500,000 are DHF / DSS patients, and the case fatality rate is as high as 5%. Without timely treatment, the case fatality rate can rise to 50%. In recent years, in endemic areas, the incidence of DHF / DSS has been increasing significantly, and has become a serious public health problem. But so far, the pathogenesis of DF, DHF and DSS is still not very clear, and there is a lack of safe and e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K19/00A61K39/12A61P31/14G01N33/569
CPCY02A50/30
Inventor 田衍平陈宗涛徐小峰
Owner ARMY MEDICAL UNIV